of borderline significanceP = .059
For CYP1A2, increasing BMI gave a negative estimate for the drug/metabolite ratio of borderline significance ( P = .059), that is a possible increase in metabolic activity.
For CYP1A2, increasing BMI gave a negative estimate for the drug/metabolite ratio of borderline significance ( P = .059), that is a possible increase in metabolic activity.
For CYP1A2, increasing BMI increased the metabolic activity with borderline significance (change in the CYP1A2 drug/metabolite ratio per unit change in BMI = –0.107; CI –0.220 to 0.005; P = .059).